# US 5,702,886 A · Chromosome I8Q loss and prognosis in colorectal cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,702,886 A
- Document ID: US5702886A
- Status: Granted
- Kind: A
- Application number: 08/318,241
- Filed: 1994-10-05
- Granted: 1997-12-30
- Earliest claimed: 1994-10-05
- Assignees: The Johns Hopkins University
- Inventors: Bert Vogelstein; Kenneth W. Kinzler; Stanley Hamilton
- Web page: https://patentgrep.com/patent/US5702886A

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/118: Prognosis of disease development
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

To examine the status of chromosome 18q, polymorphic genetic markers and DNA from formalin-fixed, paraffin-embedded tumors are employed. DNA from normal tissue is used as a comparison. The status of chromosome 18q is prognostic of the survival among stage II and stage III colorectal cancer patients.

## Claims

### Claim 1

A method of determining prognosis of a patient having a TNM stage II colorectal cancer, consisting of the steps of:
determining the presence or absence of two or more polymorphic genetic markers on chromosomes 18q in tumor tissue of the patient;
determining the presence or absence of said two or more polymorphic genetic markers on chromosome 18q in non-neoplastic tissue of the patient; a polymorphic marker which is absent in said tumor tissue but present in said non-neoplastic tissue, indicating a somatic loss of markers on chromosome 18q; and
ascertaining a predicted survival rate for the patient by applying survival outcome data obtained from a population of patients consisting of TNM stage II colorectat cancer patients in which somatic loss of polymorphic markers on chromosome 18q has been measured and used to divide the population of patients into two groups, wherein those with a somatic loss of a polymorphic marker on chromosome 18q are in a first group and those with no somatic loss of a polymorphic on chromosome 18q are in a second group, wherein the survival rate of the first group is provided to the patient if the patient is determined to have a somatic loss of a polymorphic marker and the survival rate of the second group is provided to the patient if the patient is determined to have no somatic loss of a polymorphic marker.